In this article, we will discuss Olaparib (Description-10). So, let’s get strarted. Drug Interactions Based on the data from a drug-interaction trial (n=57), the AUC and Cmax of olaparib increased by 170% and 42%, respectively, when Olaparib was administered in combination with itraconazole, a strong CYP3A inhibitor. Simulations suggested that a moderate CYP3A inhibitor (fluconazole) […]
In this article we will discuss Olaparib (Description-9)
In this article, we will discuss Olaparib (Description-8). So, let’s get started. Metabolism In vitro, CYP3A4/5 were shown to be the enzymes primarily responsible for the metabolism of Olaparib. Following oral dosing of 14C-olaparib to female patients, unchanged Olaparib accounted for the majority of the circulating radioactivity in plasma (70%). It was extensively metabolized with […]
In this article, we will discuss Olaparib (Description-7). So, let’s get started. Distribution Olaparib had a mean (± standard deviation) apparent volume of distribution of 158 ± 136 L after a single 300 mg dose of olaparib. The in vitro protein binding of olaparib is approximately 82%
In this article, we will discuss Olaparib (Description-6). So, let’s get started. Co-administration of a high fat meal with Olaparib slowed the rate (tmax delayed by 2.5 hours) of absorption, but did not significantly alter the extent of Olaparib absorption (mean AUC increased by approximately 8%).